1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO 2020: Positive Early Data For Keytruda/Lenvima In Liver, Kidney Cancer

But Tecentriq/Avastin Looms In 1L HCC

 
• By Ian Haydock

Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.

Group of Diverse Hands Together Joining Concept - Image
Better Together • Source: Shutterstock

Merck & Co. Inc. and partner Eisai Co. Ltd. have released further data they see as backing up their belief in the power of a combination of the US firm’s blockbuster immuno-oncology therapy Keytruda (pembrolizumab) with Japan-based Eisai’s Lenvima (lenvatinib) across multiple indications.

The two companies are co-developing and co-commercializing Lenvima, an oral multi tyrosine kinase inhibitor, both alone and in combination with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

More from Conferences